Wire · opportunities
FDA plans to release more CRLs as controversial policy resumes
◆ Sectors
Digital Health
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 16 July 2026 · Fusion42 review
The FDA is resuming its policy of publicly releasing drug rejection letters (CRLs) after a three-month pause, with redaction procedures now formalized to address industry concerns over competitive harm and disclosure of trade secrets.
This Wire brief sits within Fusion42's coverage of Digital Health.
◆ ◆ The Wire takeaway
Your competitor's rejection letters are now public documents. Every failed trial, every manufacturing flag, every clinical shortcut that cost them years—you'll see it weeks after they do, and you can use it to accelerate your own path.
◆ Coverage
1 source · 16 Jul 2026
◆ Related on Wire
◆ Topics
Digital Healthfda-crl-releasedrug-approval-transparencyregulatory-disclosurecompetitive-intelligence